Therapeutic use of transfer factor.
Transfer Factor (TF) was produced by ultrafiltration of repeatedly frozen and thawed, pooled buffy coats of healthy blood donors. One unit of TF Zürich was defined as the cell extract originating from 1 - 2 x 10-9 leucocytes. In collaboration with physicians and immunologists, 409 units TF have been given to 45 patients. Besides local pain and occasional fever no side effects were observed. Immune conversions and beneficial clinical effects were seen in 11 and 10 patients, respectively, out of 12 patients with chronic candidiasis. Immune conversion was also observed in patients with multiple sclerosis, while the clinical effects cannot yet be judged. The series also included patients with subacute sclerosing panencephalitis, HBAg-positive disorders, various immunodeficiency diseases, malignant malanoma and miscellaneous tumours. Immune conversion occurred only occasionally and the clinical effect was either non-existent or not judgeable. In the discussion the results of other investigators using TF therapy are included.
D000293:Adolescent; D000328:Adult; D002177:Candidiasis / Q000188:drug therapy; D002648:Child; D005260:Female; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D008222:Lymphokines / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy
D008222:Lymphokines